Update on Benign and Malignant Hepatobiliary and Pancreatic Disease

Friday, Oct. 23 – Saturday, Oct. 24, 2015
Seattle
Faculty

**COURSE DIRECTORS:**

Flavio G. Rocha, MD, FACS  
Liver, Pancreas and Biliary Surgery  
Co-Director, Research  
Digestive Disease Institute at Virginia Mason, Seattle, Wash.

Adnan A. Alseidi, MD, EdM, FACS  
Liver, Pancreas, Biliary and Endocrine Surgery  
Director, HepatoPancreatoBiliary Surgical Fellowship  
Associate Program Director, General Surgery Residency  
Digestive Disease Institute at Virginia Mason, Seattle, Wash.

W. Scott Helton, MD, FACS  
Director, Liver, Biliary and Pancreas Surgery Center of Excellence  
Digestive Disease Institute at Virginia Mason, Seattle, Wash.

**KEYNOTE SPEAKER:**

Michael I. D’Angelica, MD  
Enid A. Haupt Chair in Surgery  
Director, Hepatopancreatobiliary Fellowship Program  
Director, Surgical Oncology Fellowship Program  
Memorial Sloan Kettering Cancer Center, New York City, New York

**DIGESTIVE DISEASE INSTITUTE AT VIRGINIA MASON FACULTY:**

Thomas R. Biehl, MD, FACS  
Deputy Chief, Department of Surgery  
Head, Section of General, Thoracic and Vascular Surgery

Kimberly Bertens, MD, MPH, FRCSC  
Clinical Fellow, HepatoPancreatoBiliary Surgical Fellowship

Blaire E. Burman, MD, MAS  
Gastroenterologist and Hepatologist

David L. Coy, MD, PhD  
HepatoPancreatoBiliary Radiologist

Mehran Fotoohi, MD  
Section Head, Interventional Radiology and Radiology Computer Applications  
Interventional Radiologist

Michael Gluck, MD, FASGE, AGAF  
Chief of Medicine  
Gastroenterologist

Ellen Hauptmann, MD  
Interventional Radiologist

Shayan Irani, MD, FASGE  
Associate Director, Pancreatic Center of Excellence

Bruce B. Lin, MD  
Hematologist-Oncologist

Thomas W. Malpass, MD  
Hematologist-Oncologist  
Medical Director, Palliative Care Service

**Accreditation with Commendation:** The Virginia Mason Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Update on Benign and Malignant Hepatobiliary and Pancreatic Disease

Disorders of the hepatopancreatobiliary system can be broad and complex. Their management typically requires the expertise of several specialties in different areas of medicine including gastroenterology, surgery, oncology, diagnostic and interventional radiology and hepatology. This course is designed to provide a comprehensive review of both benign and malignant disease of the liver and pancreas, including: etiology, risk factors, early diagnosis, staging, revised consensus guidelines and the latest evidence based practices, the importance of multidisciplinary care, current research and future directions of care. Teaching methods include lectures, case discussions and question and answer with faculty.

TARGET AUDIENCE: This course is appropriate for internists, oncologists, surgeons, gastroenterologists and radiologists. This course may also be of interest to physician assistants, nurse practitioners, and other mid-level providers with an interest in hepatobiliary and pancreatic disease.

OBJECTIVES: At the conclusion of this activity, participants should be able to:

- Discuss the rationale, approach and perioperative outcomes of hepatic resection for metastatic colon cancer
- Discuss local pathways for management and surveillance of cystic neoplasms
- Manage the indeterminate biliary stricture of autoimmune cholangiopathy
- Assess options for surgical and non-surgical management of benign HPB lesions
- Specify methods to avoid bile duct injuries during cholecystectomy
- Determine when surgical repair of bile duct injury should be performed early or delayed
- Summarize the background and history of the treatment of metastatic colon cancer
- Describe the chemotherapeutic approaches to management of mCRC with liver metastases
- Discuss the application and indications for hepatic artery infusional chemotherapy in liver cancer
- Discuss how chronic viral hepatitis (HBV and HCV) lead to liver cancer
- Assess the role of endoscopy in malignant biliary obstruction
- Review the staging and work-up of bile duct and pancreas cancers
- Summarize current surgical and medical management guidelines for pancreas neuroendocrine tumors
- Describe supportive care options for pancreas cancer patients

DAY 1: Friday, October 23
Focus on Benign Hepatobiliary and Pancreatic Disease

7:00 a.m.  Registration, continental breakfast
7:30 a.m.  Grand Rounds Presentation: Hepatic Resection for Metastatic Colorectal Cancer | Michael D’Angelica, MD
8:30 a.m.  Break
8:45 a.m.  Opening Remarks and Overview of Objectives
            Flavio Rocha, MD; Adnan Alseidi, MD; and Scott Helton, MD

SESSION I: PANCREATITIS AND CYSTIC NEOPLASMS
9:00 a.m.  Medical Management of Acute and Chronic Pancreatitis
            Michael Gluck, MD
9:25 a.m.  Surgery for Chronic Pancreatitis | Scott Helton, MD
9:50 a.m.  Break
10:10 a.m. Cystic Neoplasms: When to Resect or Observe? | Adnan Alseidi, MD
10:45 a.m. Pancreas Potpourri: Cases and Panel Discussion
            Panel: Michael Gluck, MD; Scott Helton, MD and Adnan Alseidi, MD
11:45 a.m.  Lunch (provided)

SESSION II: BENIGN HEPATOBILIARY DISEASE
12:30 p.m.  Imaging of Benign Liver Tumors  |  David Coy, MD
12:55 p.m.  Autoimmune Cholangiopathy  |  Shayan Irani, MD
1:20 p.m.  Surgery for Benign HPB Lesions  |  Thomas Biehl, MD
1:45 p.m.  Break

SESSION III:BILE DUCT INJURY
2:00 p.m.  Culture of Safety for Prevention  |  Thomas Biehl, MD
2:25 p.m.  Diagnostic, Endoscopic and Interventional Techniques
Ellen Hauptmann, MD
2:50 p.m.  Definitive Surgical Repair  |  Adnan Alseidi, MD
3:15 p.m.  Benign Hepatobiliary Disease: Cases and Panel Discussion
Panel: David Coy, MD; Shayan Irani, MD; Thomas Biehl, MD;
Ellen Hauptmann, MD and Adnan Alseidi, MD
4:15 p.m.  Wrap-Up and Questions
4:30 p.m.  Adjourn

DAY 2: Saturday, October 24
Focus on Malignant Hepatobiliary and Pancreatic Disease

7:30 a.m.  Registration, continental breakfast

SESSION IV: PRIMARY AND METASTATIC LIVER TUMORS
8:00 a.m.  Historical Perspective and Epidemiology of Metastatic Colon Cancer
Flavio Rocha, MD
8:15 a.m.  An Oncologist’s Perspective in Management of mCRC with Liver Metastases  |  Bruce Lin, MD
8:45 a.m.  Keynote Address: Hepatic Artery Infusional Chemotherapy for Primary and Metastatic Disease  |  Michael D’Angelica, MD
9:45 a.m.  Break
10:00 a.m.  HBV, HCV and HCC  |  Blaire Burman, MD
10:25 a.m.  Ablate, Resect or Transplant?  |  Scott Helton, MD
10:50 a.m.  TACE, Y90 and IRE  |  Mehran Fotoohi, MD
11:15 a.m.  Liver Tumor Board: Cases and Panel  |  Panel: Michael D’Angelica, MD; Blaire Burman, MD; Scott Helton, MD and Mehran Fotoohi, MD
12:00 p.m.  Lunch (provided)

SESSION V: CHOLANGIOPANCICONCARINOMA AND PANCREATIC NEUROENDOCRINE TUMORS
12:45 p.m.  Diagnostic Techniques and Role of Stenting for HPB Malignancies
Shayan Irani, MD
1:10 p.m.  Surgical Management of Bile Duct Cancer  |  Flavio Rocha, MD
1:35 p.m.  Surgical and Non-Surgical Treatment of Primary and Metastatic PNETs
Kimberly Bertens, MD
2:00 p.m.  Break

SESSION VI: PANCREATIC ADENOCARCINOMA
2:10 p.m.  Management of Locally Advanced Disease  |  Flavio Rocha, MD
2:55 p.m.  Palliative Care for Pancreatic Cancer  |  Thomas Malpass, MD
3:20 p.m.  Pancreatobiliary Tumor Board: Cases and Panel Discussion
Panel: Shayan Irani, MD; Flavio Rocha, MD; Kimberly Bertens, MD and Thomas Malpass, MD
4:20 p.m.  Final Questions and Closing Remarks
4:35 p.m.  Adjourn
To register, complete the form below and send via:

MAIL: Virginia Mason CME Dept.
1100 9th Ave, D3-CME
Seattle, WA 98101

PHONE: (206) 341-0142

FAX: (206) 341-1480

E-MAIL: cme@virginiamason.org

WEB: VirginiaMasonCME.org

Cancellation and Refund Policy: Refunds will be made for a fee of $25 if written notice of cancellation is received at least 14 calendar days prior to the activity.

Registration
Update on Benign and Malignant Hepatobiliary and Pancreatic Disease
Friday, Oct. 23 – Saturday, Oct. 24, 2015

Credit Designation: Complete Course: Virginia Mason designates this live activity for a maximum of 15.0 AMA PRA Category 1 Credits™. Day 1 or Day 2 Only: Virginia Mason designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Location: The course will be held at Virginia Mason Hospital and Seattle Medical Center in the Volney Richmond Auditorium in Lindeman Pavilion, Level One, 1201 Terry Avenue (between Seneca and University Streets) in Seattle, Washington. For further information, please contact the CME Department at (206) 341-0142 or e-mail cme@virginiamason.org.

Please print clearly

NAME

DEGREE/CREDS

SPECIALTY

ORGANIZATION

ADDRESS

CITY/STATE/ZIP

PHONE

E-MAIL

☐ Please add me to your e-mail list for news of upcoming CME courses at Virginia Mason.

TUITION:

☐ Complete Course: $375  ☐ Day 1 Only: $200  ☐ Day 2 Only: $200

☐ Check enclosed. Make check payable to Virginia Mason CME

☐ Please charge my:  ☐ VISA  ☐ MasterCard  ☐ American Express  ☐ Discover

CARD NUMBER

EXPIRATION DATE

CARDHOLDER NAME

SIGNATURE